Details
Stereochemistry | RACEMIC |
Molecular Formula | C13H28N4O2 |
Molecular Weight | 272.387 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 2 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@@H](NCC(C)(C)CN[C@H](C)C(\C)=N\O)C(\C)=N\O
InChI
InChIKey=BPNZYADGDZPRTK-UDUYQYQQSA-N
InChI=1S/C13H28N4O2/c1-9(11(3)16-18)14-7-13(5,6)8-15-10(2)12(4)17-19/h9-10,14-15,18-19H,7-8H2,1-6H3/b16-11+,17-12+/t9-,10-/m1/s1
Molecular Formula | C13H28N4O2 |
Molecular Weight | 272.387 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 2 |
Optical Activity | UNSPECIFIED |
Technetium (99mTc) exametazime is a radiopharmaceutical agent, which is known as trade name Ceretec. The Ceretec kit is supplied as five packs of three vials for use in the preparation of a technetium Tc99m exametazime intravenous injection as a diagnostic radiopharmaceutical. When technetium Tc99m pertechnetate is added to exametazime in the presence of stannous reductant, a lipophilic technetium Tc99m complex is formed. This lipophilic complex is the active moiety. It converts at approximately 12%/hour to less lipophilic species. When the secondary complex is separated from the lipophilic species, it is unable to cross the blood-brain-barrier. The useful life of the reconstituted agent is limited to 30 minutes. This complex is used as an adjunct in the detection of altered regional cerebral perfusion in stroke. And in addition, is indicated for leukocyte labeled scintigraphy as an adjunct in the localization of intra-abdominal infection and inflammatory bowel disease. Also exist clinical trials, where this complex is used for diagnostic purposes in Crohn's Disease and in vascular prosthesis infection.
Approval Year
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Diagnostic | CERETEC Approved UseTechnetium Tc99m exametazime scintigraphy may be useful as an adjunct in the detection of altered regional cerebral perfusion in stroke. Tc99m exametazime is indicated for leukocyte labeled scintigraphy as an adjunct in the localization of intra-abdominal infection and inflammatory bowel disease. Launch Date1988 |
|||
Diagnostic | Unknown Approved UseUnknown |
|||
Diagnostic | CERETEC Approved UseTechnetium Tc99m exametazime scintigraphy may be useful as an adjunct in the detection of altered regional cerebral perfusion in stroke. Tc99m exametazime is indicated for leukocyte labeled scintigraphy as an adjunct in the localization of intra-abdominal infection and inflammatory bowel disease. Launch Date1988 |
|||
Diagnostic | CERETEC Approved UseTechnetium Tc99m exametazime scintigraphy may be useful as an adjunct in the detection of altered regional cerebral perfusion in stroke. Tc99m exametazime is indicated for leukocyte labeled scintigraphy as an adjunct in the localization of intra-abdominal infection and inflammatory bowel disease. Launch Date1988 |
|||
Diagnostic | CERETEC Approved UseTechnetium Tc99m exametazime scintigraphy may be useful as an adjunct in the detection of altered regional cerebral perfusion in stroke. Tc99m exametazime is indicated for leukocyte labeled scintigraphy as an adjunct in the localization of intra-abdominal infection and inflammatory bowel disease. Launch Date1988 |
PubMed
Title | Date | PubMed |
---|---|---|
"Luxury perfusion" with 99mTc-HMPAO and 123I-IMP SPECT imaging during the subacute phase of stroke. | 1990 |
|
[Therapy and diagnosis of emergency shock patients]. | 1991 Dec 10 |
|
Comparison of 99m technetium hexamethylpropylene-amine oxime labelled leucocyte with 111-indium tropolonate labelled granulocyte scanning and ultrasound in the diagnosis of intra-abdominal abscess. | 1995 Oct |
|
Effects of methylene blue stabilizer on in vitro viability and chemotaxis of 99mTc-exametazime-labeled leukocytes. | 2002 Jul |
Patents
Sample Use Guides
The normal adult (70 kg) dose is 0.259-0.925 GBq (7-25 mCi) as Tc99m labeled leukocytes by intravenous injection. Optimal planar imaging is between 2-4 hours. Do not use methylene blue in the preparation of the Tc99m labeled leukocytes.
Cerebral Scintigraphy: The recommended dose range for i.v. administration, of reconstituted sodium pertechnetate Tc99m exametazime (with or without methylene blue) in the average adult (70 kg) is 370-740 MBq (10-20 mCi).
Dynamic imaging may be performed between 0 to 10 minutes following injection. Static imaging may be performed from 15 minutes up to 6 hours after injection.
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/12097465
Whole blood (480 mL) was obtained from each of 3 healthy donors and divided equally into eight 60-mL aliquots. Two aliquots from each of the 3 subjects were used as a control (i.e., leukocytes were not labeled with either nonstabilized or stabilized 99mTc-exametazime) in this study. The remaining 6 aliquots from each of the 3 subjects were divided equally into the following formulation groups: (a) leukocytes labeled with nonstabilized 99mTc-exametazime, (b) leukocytes labeled with stabilized 99mTc-exametazime containing 250 microg methylene blue, and (c) leukocytes labeled with stabilized 99mTc-exametazime containing 500 microg methylene blue. It was revealed that, the methylene blue/phosphate buffer stabilizer (250 or 500 microg methylene blue) did not affect the cell membrane integrity, chemotactic capacity, labeling efficiency, in vitro stability, or complete blood count of leukocytes labeled with stabilized 99mTc-exametazime.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 17:51:06 GMT 2023
by
admin
on
Sat Dec 16 17:51:06 GMT 2023
|
Record UNII |
G29272NCKL
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C1937
Created by
admin on Sat Dec 16 17:51:06 GMT 2023 , Edited by admin on Sat Dec 16 17:51:06 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
m5223
Created by
admin on Sat Dec 16 17:51:06 GMT 2023 , Edited by admin on Sat Dec 16 17:51:06 GMT 2023
|
PRIMARY | Merck Index | ||
|
DTXSID1057614
Created by
admin on Sat Dec 16 17:51:06 GMT 2023 , Edited by admin on Sat Dec 16 17:51:06 GMT 2023
|
PRIMARY | |||
|
105613-48-7
Created by
admin on Sat Dec 16 17:51:06 GMT 2023 , Edited by admin on Sat Dec 16 17:51:06 GMT 2023
|
PRIMARY | |||
|
G29272NCKL
Created by
admin on Sat Dec 16 17:51:06 GMT 2023 , Edited by admin on Sat Dec 16 17:51:06 GMT 2023
|
PRIMARY | |||
|
100000082322
Created by
admin on Sat Dec 16 17:51:06 GMT 2023 , Edited by admin on Sat Dec 16 17:51:06 GMT 2023
|
PRIMARY | |||
|
9552071
Created by
admin on Sat Dec 16 17:51:06 GMT 2023 , Edited by admin on Sat Dec 16 17:51:06 GMT 2023
|
PRIMARY | |||
|
SUB07355MIG
Created by
admin on Sat Dec 16 17:51:06 GMT 2023 , Edited by admin on Sat Dec 16 17:51:06 GMT 2023
|
PRIMARY | |||
|
Z-40
Created by
admin on Sat Dec 16 17:51:06 GMT 2023 , Edited by admin on Sat Dec 16 17:51:06 GMT 2023
|
PRIMARY | |||
|
DB11179
Created by
admin on Sat Dec 16 17:51:06 GMT 2023 , Edited by admin on Sat Dec 16 17:51:06 GMT 2023
|
PRIMARY | |||
|
CHEMBL2218892
Created by
admin on Sat Dec 16 17:51:06 GMT 2023 , Edited by admin on Sat Dec 16 17:51:06 GMT 2023
|
PRIMARY | |||
|
62153
Created by
admin on Sat Dec 16 17:51:06 GMT 2023 , Edited by admin on Sat Dec 16 17:51:06 GMT 2023
|
PRIMARY | RxNorm | ||
|
G29272NCKL
Created by
admin on Sat Dec 16 17:51:06 GMT 2023 , Edited by admin on Sat Dec 16 17:51:06 GMT 2023
|
PRIMARY | |||
|
C65608
Created by
admin on Sat Dec 16 17:51:06 GMT 2023 , Edited by admin on Sat Dec 16 17:51:06 GMT 2023
|
PRIMARY | |||
|
6094
Created by
admin on Sat Dec 16 17:51:06 GMT 2023 , Edited by admin on Sat Dec 16 17:51:06 GMT 2023
|
PRIMARY | |||
|
C078058
Created by
admin on Sat Dec 16 17:51:06 GMT 2023 , Edited by admin on Sat Dec 16 17:51:06 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |